Valsartan

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

Retrieved on: 
Thursday, January 4, 2024
Medical Supplies, Other Retail, Clinical Trials, Specialty, Biotechnology, Health, Pharmaceutical, General Health, Retail, Amneal Pharmaceuticals, Capsule, Medication, Valsartan, Tranexamic acid, Spironolactone, Senior, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022.
  • In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables.
  • New injectable products added include potassium phosphate vials, tranexamic acid and esmolol intravenous bags.
  • In addition, Amneal launched several key new retail products in the fourth quarter, including spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules.

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Urine, Patient, Medical Subject Headings, Heart failure, Marketing, Nitrosamine, Quality of life, Kidney, Sacubitril, INN, Pediatrics, Natriuresis, Death, Valsartan, Woman, Failure, Hypotension, ATC, System, Blood, International, Sodium, European, Disease, Angioedema, Diabetes, Tissue, Profile, Language, Ageing, Mouth, Heart, Enalapril, Hyperkalemia, Angiotensin, Water, European Medicines Agency, ACE, Tablet, Select, Liver disease, Anatomy, Medicine, Fibrosis, IIA, Science, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Urine, Patient, Medical Subject Headings, Heart failure, Marketing, Nitrosamine, Quality of life, Kidney, Sacubitril, INN, Pediatrics, Natriuresis, Death, Valsartan, Woman, Failure, Hypotension, ATC, System, Blood, International, Sodium, European, Disease, Angioedema, Tissue, Profile, Diabetes, Language, Ageing, Heart, Enalapril, Angiotensin, Hyperkalemia, Water, European Medicines Agency, ACE, Tablet, Select, Liver disease, Anatomy, Medicine, Fibrosis, IIA, Science, Medical device

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Individuals and Entities who Consumed and/or Paid for Valsartan or Valsartan‐Containing Drugs, a Class Action Lawsuit Could Affect Your Rights

Retrieved on: 
Monday, December 4, 2023
Nitrosamine, Migliaccio, Clerk, Plaintiff, Notice, LLP, Subclass, Class, District court, Active ingredient, NDEA, NDMA, Judgement, PO, Ritalin class-action lawsuits, Kanner, Court, TPP, Third party, Pharmaceutical industry, Defendant, Losartan, Lawsuit, Valsartan

The Court has not decided whether the Defendants did anything wrong or whether the Plaintiffs' claims have merit.

Key Points: 
  • The Court has not decided whether the Defendants did anything wrong or whether the Plaintiffs' claims have merit.
  • If you qualify as a member of a Class, you have the right to participate as a class member or to opt out.
  • You may visit the Case Website to register for case updates regarding the Lawsuit and any potential recovery or benefits to class members.
  • Opt-Out: All individuals and entities that satisfy a Class definition will be automatically included in the Class unless they choose to opt-out from the Class and Lawsuit entirely.

Slack Davis Sanger: Class-action lawsuits against generic Valsartan manufacturers moves forward

Retrieved on: 
Monday, February 13, 2023
Pharmacy, David Gal, NDEA, NDMA, Personal injury, Plasma protein binding, Failure, Hypertension, Carcinogen, FDA, MDL, Name, Blood pressure, Dietary supplement, Pharmaceutical industry, Losartan, Valsartan

Valsartan is a popular generic prescription medicine indicated to treat hypertension, and originally sold under the trade names of DIOVAN® and EXFORGE®.

Key Points: 
  • Valsartan is a popular generic prescription medicine indicated to treat hypertension, and originally sold under the trade names of DIOVAN® and EXFORGE®.
  • Since 1993, Slack Davis Sanger has been serving clients nationally and internationally with personal injury claims, wrongful death, and medical malpractice claims.
  • With a combined experience of more than 250 years, Slack Davis Sanger attorneys have extensive experience in litigation involving class action lawsuits and whistleblower cases.
  • For more information or to speak with John Davis, please contact Marketing Manager Stephanie Eitrheim at Slack Davis Sanger at 512-225-5322.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022
Patient, Medication, Research, Marketing, COVID-19, Growth, Pramipexole, Company, Tax, JBM, Febuxostat, Guangdong-Hong Kong-Macau Greater Bay Area, Vaccination, Acceleration, Development, Department, Depreciation, EBITDA, Big White Duel, GMP, Acute promyelocytic leukemia, Idarubicin, Department of Health (Hong Kong), Fosun International, Fosun Pharma, Diabetes, Medical device, Conditional sentence, Greater, Dexmedetomidine, Health care, Public sector, Hospital, Board, PIC/S, HK, Analgesic, Sale, Amlodipine, The Group, University, Cardiovascular disease, Tablet, Immunity, Generic drug, Pharmaceutical industry, Vaccine, Valsartan, Group, Vaccine, Telmisartan, Brimonidine

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

Retrieved on: 
Monday, May 23, 2022
Part, Valsartan, Risk, AOBP, Hypertension, African Americans, Degenerative disease, Blood pressure, MD, Patient, Amlodipine, Association, IDIA, Hydrochlorothiazide, Stroke, ERA, BMI, LR, Kidney failure, Life, Safety, ETA, Observation, Prevalence, Diagnosis, ETB, Pharmaceutical industry

Aprocitentan significantly reduced blood pressure when added to standardized combination background antihypertensive therapy in patients with resistant hypertension over 48 weeks of treatment.

Key Points: 
  • Aprocitentan significantly reduced blood pressure when added to standardized combination background antihypertensive therapy in patients with resistant hypertension over 48 weeks of treatment.
  • To confirm a diagnosis of resistant hypertension and exclude pseudo resistant hypertension, 1965 patients entered a thorough 12-week screening period.
  • 2020
    In May 2017, the results of a double-blind, randomized, placebo-controlled with an active-reference arm, dose-finding study with aprocitentan in patients with essential hypertension, were reported.
  • The safety population included 327 patients in the aprocitentan groups, 82 patients in the placebo group and 81 in the lisinopril group.

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Pharmaceutical, Health, RDY, U.S. Securities and Exchange Commission, NYSE, Dermatology, Pregnancy, CIS, Risk factor (finance), BSE, API, Valsartan, Mortality, USFDA, Security (finance), Pain management, USP, NSE, Coronavirus, Food, Death, Tablet, Epidemic, Industry, Lists of disasters, Disease, Pandemic, Novartis, COVID-19, Time-invariant system, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Mission statement, Health, Risk, Generic drug, Pharmaceutical industry

The Diovan brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Key Points: 
  • The Diovan brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.
  • Dr. Reddys Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.
  • Please click here for full prescribing information including boxed warning: https://www.drreddys.com/pil/150084612-Valsartan-Tablets_Outsert-v_10.pdf
    When pregnancy is detected, discontinue Valsartan as soon as possible.
  • (5.1)
    Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Lowey Dannenberg, P.C. and The Dugan Law Firm, APLC Announce Court's Certification of Class Action Involving Third-Party Payors' Payment or Reimbursement for Some or All of the Purchase Price of Generic Nexium (esomeprazole magnesium), Brand or Generic Di

Retrieved on: 
Friday, November 5, 2021
Nexium, Valsartan, Person, South African Class ES, City, Pharmacy, AB, Plasma protein binding, Insurance, MDL Information Systems, TPP Nikola Tesla, Judgement, Ranbaxy Laboratories, John Joseph Moakley United States Courthouse, Maryland Office of the Public Defender, Court, MDL, District, FDA, TPP, Generic drug, Health insurance, Pharmaceutical industry, Maple syrup

Your rights may be affected by a class action lawsuit regarding the price paid for generic Nexium, brand and generic Diovan, and brand and generic Valcyte by Third-Party Payors ("TPPs") filed against Defendants Sun Pharmaceutical Industries, Ltd. And Ranbaxy, Inc.

Key Points: 
  • Your rights may be affected by a class action lawsuit regarding the price paid for generic Nexium, brand and generic Diovan, and brand and generic Valcyte by Third-Party Payors ("TPPs") filed against Defendants Sun Pharmaceutical Industries, Ltd. And Ranbaxy, Inc.
  • The case name is In Re Ranbaxy Generic Drug Application Antitrust Litigation, MDL No.
  • You are a member of the Class(es) if you are a TPP and you purchased or provided reimbursement for prescription drugs as described as follows:
    Generic Nexium Nationwide Class.
  • Any changes to the date or location of the trial will be posted to the case website.

Hypertension in CKD Markets: Diuretics, RAS Blockade, B-Blockers, Calcium Channel Blockers - Global Size, Share, Outlook, and Opportunity Analysis, 2020-2021 & 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021
Health, Pharmaceutical, Chemical compounds, Antihypertensive agents, Drugs, Chemistry, Carboxylic acids, Combination drugs, Sacubitril/valsartan, Sacubitril, Valsartan, Novartis, Angiotensin II receptor blocker

The "Hypertension in CKD Market, by Drug Class, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypertension in CKD Market, by Drug Class, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan).
  • According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases.
  • The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market.